Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on August 20, 2026, covering an aggregate of 240,135 shares of common stock for twenty new non-executive employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on August 20, 2026, covering an aggregate of 240,135 shares of common stock for twenty new non-executive employees. The options were granted under the company’s Amended and Restated 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $8.99, equal to the closing price of Iovance’s common stock on the grant date. The awards vest over three years: one-third on the first anniversary of each employee’s start date, and the remaining two-thirds in eight quarterly installments over the following two years, subject to continued employment.
Positive
- 240,135-share inducement option grant to twenty new non-executive employees
- Exercise price set at market closing price of $8.99 on grant date
- Three-year vesting schedule with quarterly installments supports multi-year employee retention
Negative
- Potential shareholder dilution from up to 240,135 additional shares if options are exercised
Details
News Market Reaction – IOVA
On Aug 24, the first trading day after this news, IOVA closed 2.77% below the previous close. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner recorded 9 alerts for this stock that day. Relative volume reached 5.3x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 24 session.
Key Figures
- Grant Date
- August 20, 2026
- Inducement awards
- Shares Covered
- 240,135 shares
- Aggregate stock options granted
- Recipients
- 20 employees
- New, non-executive employees
- Exercise Price
- $8.99
- Closing price on the Date of Grant
- Vesting Period
- Three years
- Each stock option
- Initial Vesting
- One-third of shares
- First anniversary of employee start date
- Quarterly Installments
- Eight installments
- Remaining shares over the next two years
Historical Context
-
Record quarterly revenue and narrowed net loss accompanied the earnings announcement.
-
The company scheduled its second-quarter financial results report and corporate update.
-
Options covering 139,930 shares were granted to seventeen new employees.
-
Options covering 140,860 shares were granted to twenty-seven new employees.
-
Amtagvi received conditional approval for advanced melanoma treatment in Australia.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
polyclonal tumor infiltrating lymphocyte medical
tumor infiltrating lymphocyte medical
inducement stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, non-executive employees.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.